GLGC Gene Logic Inc. (MM)

Gene Logic Integrates Both Xenogen's Proprietary Biophotonic Imaging Technology and Custom Animal Model Generation into Its New Drug Repositioning and Selection Business ALAMEDA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Xenogen Corporation (NASDAQ:XGEN) announced today an agreement with Gene Logic Inc. (NASDAQ:GLGC). Xenogen Biosciences Corporation, Xenogen's wholly owned subsidiary, is producing and characterizing lines of custom-produced bioluminescent animal models for Gene Logic. This deal follows a November 2004 agreement in which Gene Logic purchased Xenogen equipment and licensed Xenogen's proprietary biophotonic imaging technology. Gene Logic has integrated Xenogen's technology into its new Drug Repositioning and Selection(TM) (DRS) collaborations. Under the November 2004 agreement, Gene Logic purchased Xenogen's biophotonic imaging systems, IVIS(R) Imaging System 200 Series, and licensed the company's proprietary Living Image(R) Software and patented methods of biophotonic imaging. Under the April 2005 agreement, Gene Logic received a license grant to the customized bioluminescent animal models it is producing together with Xenogen Biosciences for use in Gene Logic's new DRS collaborations. Gene Logic has combined its own proprietary imaging methods with Xenogen's technology to form an important part of its overall drug- repositioning platform. "Xenogen's biophotonic imaging technology is one of a number of key technologies that we are in-licensing and/or developing for our new repositioning and selection program," said Louis Tartaglia, Ph.D., senior vice president and general manager, Drug Repositioning and Selection for Gene Logic. "This technology, in combination with proprietary methods developed at Gene Logic, provides us with an important new way of non-invasively imaging whole animals over time and essentially lighting up the biological processes or responses to the compound we're testing. We believe this will help us generate valuable predictive data on how a drug affects the whole system. These data are not available with conventional research methods." Gene Logic's DRS collaborations are based, in part, on technologies the company acquired in 2004 from Millennium Pharmaceuticals, Inc. These technologies include in vivo real-time imaging; disease metabolomics; disease- relevant in vitro pathway and cellular screening; and predictive and genetic ADME. When combined with Gene Logic's existing genomics and toxicogenomics capabilities and in silico analysis, DRS collaborations are designed to enable Gene Logic to help pharmaceutical partners identify alternative indications for failed, stalled or de-prioritized drug candidates, expand indications for currently marketed drugs, and prioritize and identify indications for drug candidates entering pre-clinical development. "Gene Logic has developed an exciting new business and scientific opportunity to reposition drug compounds for new indications, and we are pleased that our technology can play a role in that effort," said Pamela Contag, Ph.D., president of Xenogen Corporation. "Gene Logic recognized the benefits of Xenogen's non-invasive molecular and functional imaging technology for prioritizing targets and compound indications early in the drug discovery and development process or later in the process to find new development paths for clinical-stage drug candidates." About Xenogen Corporation Xenogen Corporation is a leading biotechnology company offering an integrated suite of biophotonic real-time in vivo imaging and genetic modification technologies that can help expedite drug discovery and development, and significantly reduce the cost and time to market for new therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and monitor biological processes within living mammals, at the molecular level, in real time. The technology provides higher quality in vivo data earlier in the drug discovery and development process. VivoVision(TM) Solutions improve discovery and pre-clinical research in multiple therapeutic areas. VivoVision(TM) Biosciences represents more than 15 years of experience in the creation and characterization of animal models, including genetic modifications, comprehensive phenotyping, compound profiling and custom design and production of light producing cells, microorganisms and animals. More information is available at http://www.xenogen.com/. Xenogen(R), Living Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation. Forward-Looking Statements This press release contains forward-looking statements regarding the performance and intended uses of our imaging products and technologies. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to many risks, uncertainties and unknown future events that could cause actual results to differ materially. Actual use and results of imaging products and technologies may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: our ability to continue to deliver our products on a timely basis; our ability to enforce our intellectual property rights or operate without infringing or misappropriating the proprietary rights of others; products, services or technologies introduced by competing companies; and other risk factors set forth in our filings with the Securities and Exchange Commission. For a discussion of these and other factors that could impact the performance or use of our imaging products and technologies and cause them to differ materially from those in the forward-looking statements, please refer to our recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q for the quarter ended June 30, 2005. We assume no obligation to update any forward-looking statements or information, which speak as of their respective dates. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Pamela R. Contag, Ph.D. http://profnet.prnewswire.com/ud_public.jsp?userid=513625 David W. Carter http://profnet.prnewswire.com/ud_public.jsp?userid=513851 DATASOURCE: Xenogen Corporation CONTACT: investors, William A. Albright of Xenogen Corporation, +1-510-291-6100, or media, Kelly McKenna of Manning Selvage & Lee, +1-415-278-3318, for Xenogen Corporation Web site: http://www.xenogen.com/

Copyright